6533b860fe1ef96bd12c39b2

RESEARCH PRODUCT

Overexpression of the insulin-like growth factor I receptor in human pheochromocytomas.

Sarah KalmbachMatthias M. WeberTimo MinnemannChristian Fottner

subject

AdultMalemedicine.medical_specialtyPheochromocytomaBiologyReceptor IGF Type 1PathogenesisEndocrinologyInternal medicinemedicineHumansRNA MessengerBinding siteReceptorMolecular BiologyMessenger RNARNAMolecular biologyRadioligand AssayReverse transcription polymerase chain reactionDissociation constantGene Expression Regulation NeoplasticEndocrinologyAdrenal MedullaFemaleProtein Binding

description

In order to determine the role of the IGF-I receptor (IGF-IR) in human pheochromocytomas we have compared the expression of the IGF-IR in normal tissues and in pheochromocytomas with regard to the IGF-IR mRNA levels and ligand binding. By semiquantitative reverse transcription polymerase chain reaction (RT-PCR), the mRNA of the IGF-IR could be detected in all samples of normal adrenomedullary cells (n=13) and pheochromocytomas (n=16). However, pheochromocytomas exhibited 2.8-fold higher mean IGF-IR mRNA levels than normal adrenomedullary cells (2.8±0.5×105 molecules/μg RNA vs 7.8±1.2×105 molecules/μg RNA; P < 0.001). This overexpression of the IGF-IR in pheochromocytomas could be confirmed at the protein level by binding studies. Radioligand assays and Scatchard analysis revealed a single class of high affinity IGF-IR binding sites with a similar dissociation constant (Kd: 0.32±0.1 nmol/l vs 0.22±0.08 nmol/l) for both normal adrenomedullary cells and pheochromocytomas. However, specific 125I-labeled IGF-I binding and the calculated receptor concentration were significantly elevated in pheochromocytomas as compared with normal adrenomedullary cells (58.3±5 vs 24.3±12 nmol/kg protein; P < 0.05). In summary, our results demonstrate significant overexpression of the IGF-IR in human pheochromocytomas. This suggests a possible role of the IGF system in the pathogenesis of adrenal neoplasia and thus IGF-IR may be a target for future therapeutic approaches.

10.1677/jme.1.01975https://pubmed.ncbi.nlm.nih.gov/16595699